Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or Obese

NCT06577090 is registered in ClinicalTrials.gov with Skye Bioscience, Inc. as lead sponsor.

NCT NCT06577090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06577090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of QW Nimacimab Injection, Compared to Placebo Injection and QW Weekly Nimacimab Injection Co-administered With Semaglutide in Participants Who Are Overweight or Obese
Lead sponsor
Skye Bioscience, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 22, 2024
Completion date
February 28, 2027
Enrollment
136 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

obesity